Jbtor Plus 20 Tablet is a combination medication containing Spironolactone 50 mg and Torasemide 20 mg, primarily indicated for the management of edema associated with congestive heart failure, liver cirrhosis, and nephrotic syndrome, as well as for the treatment of hypertension. Spironolactone is a potassium-sparing diuretic that antagonizes aldosterone receptors in the distal renal tubules, promoting sodium and water excretion while conserving potassium, thereby preventing hypokalemia. Torasemide is a loop diuretic that inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, resulting in potent diuresis and reduction of fluid overload. The synergistic action of these two agents enhances diuretic efficacy while minimizing electrolyte imbalances. Jbtor Plus 20 is typically administered orally once daily, with dosage adjustments based on clinical response and renal function. Caution is advised in patients with renal impairment, hyperkalemia, or hypersensitivity to sulfonamides. Common adverse effects may include electrolyte disturbances, hypotension, dizziness, and gastrointestinal discomfort. Regular monitoring of serum electrolytes, renal function, and blood pressure is recommended during therapy to ensure safety and therapeutic effectiveness. This combination offers a balanced approach for fluid management in patients requiring diuretic therapy.